ESMO News

New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer

noreply@esmo.org — Thu, 02 Jul 2026 14:07:00 +00:00

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026

Record Impact Factor for Annals of Oncology Highlights Growing Influence of ESMO Journals

noreply@esmo.org — Thu, 02 Jul 2026 13:07:00 +00:00

The latest Impact Factors, released in June 2026 by Clarivate’s Journal Citation Reports (JCR), reflect the expanding reach and influence of ESMO Journals, underlining their role in advancing high-quality science, stimulating critical dialogue, and shaping the future of oncology research and clinical practice worldwide

Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma

noreply@esmo.org — Thu, 02 Jul 2026 07:07:00 +00:00

Findings from the MonumenTAL-3 study

FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy

noreply@esmo.org — Wed, 01 Jul 2026 07:07:00 +00:00

Evidence for efficacy is based on the results from the CADENZA study

Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC

noreply@esmo.org — Tue, 30 Jun 2026 07:06:00 +00:00

Findings from the HARMONi-6 study

Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma

noreply@esmo.org — Tue, 30 Jun 2026 07:06:00 +00:00

Findings from the ASTRUM-006 study

EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan

noreply@esmo.org — Fri, 26 Jun 2026 08:06:00 +00:00

New indication concerns the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours

High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality

noreply@esmo.org — Thu, 25 Jun 2026 08:06:00 +00:00

Findings from the analyse of trends in cervical cancer mortality

FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC

noreply@esmo.org — Wed, 24 Jun 2026 07:06:00 +00:00

Evidence for efficacy is based on the results from the TROPION-Breast02 study

Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions

noreply@esmo.org — Tue, 23 Jun 2026 07:06:00 +00:00

Findings from the WU-KONG28 study

No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection

noreply@esmo.org — Mon, 22 Jun 2026 07:06:00 +00:00

EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin

noreply@esmo.org — Fri, 19 Jun 2026 07:06:00 +00:00

New indication concerns combination with pembrolizumab, as neoadjuvant and adjuvant treatment in patients with resectable MIBC who are ineligible for cisplatin

ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems

noreply@esmo.org — Fri, 19 Jun 2026 07:06:00 +00:00

ESMO joined the World Health Organization’s (WHO) Global Clinical Trials Forum (GCTF), reinforcing its long-standing collaboration with WHO and its commitment to advancing more equitable, high-quality clinical research worldwide

Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis

noreply@esmo.org — Thu, 18 Jun 2026 07:06:00 +00:00

Findings from the SENTRY study

FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer

noreply@esmo.org — Wed, 17 Jun 2026 07:06:00 +00:00

FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki

ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026

noreply@esmo.org — Tue, 16 Jun 2026 14:06:00 +00:00

Joined-up health policy-making at the EU level is essential for improving the quality of cancer care, driving the development of innovative treatments, and addressing the medical needs of patients with cancer.

Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment

noreply@esmo.org — Tue, 16 Jun 2026 07:06:00 +00:00

Findings from the MajesTEC-9 study

ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer Plan

noreply@esmo.org — Mon, 15 Jun 2026 08:06:00 +00:00

Keeping cancer high on the EU’s health policy agenda is essential for improving the quality of cancer treatments, supporting the profession and practice of medical oncology, and ultimately delivering tangible solutions that benefit patients with cancer.

Adding Talazoparib to Enzalutamide Prolongs Imaging-Based PFS in Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer with Alterations in HRR Genes

noreply@esmo.org — Mon, 15 Jun 2026 07:06:00 +00:00

Findings from the TALAPRO-3 study

Ahead of a Key Meeting of EU Health Ministers, ESMO Calls for Robust Measures to Improve the Delivery of Cancer Care to Patients and Achieve the Goals of Europe’s Beating Cancer Plan

noreply@esmo.org — Sun, 14 Jun 2026 22:06:00 +00:00

Keeping health on the forefront of the EU’s political agenda is essential for enhancing the quality of cancer care across Europe, enabling the development of new cancer treatments, empowering medical oncologists, and addressing the needs of patients.